Stockscreener 앱 받기
19.96
2.00%
0.395
전일 마감가:
$19.57
열려 있는:
$19.73
하루 거래량:
344.87K
Relative Volume:
0.20
시가총액:
$1.79B
수익:
$217.42M
순이익/손실:
$-243.25M
주가수익비율:
-7.1426
EPS:
-2.7952
순현금흐름:
$-278.35M
1주 성능:
+0.23%
1개월 성능:
-4.08%
6개월 성능:
-3.80%
1년 성능:
+27.47%
1일 변동 폭
$19.70
$20.40
1주일 범위
$19.17
$20.88
52주 변동 폭
$12.99
$25.59
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
명칭
Syndax Pharmaceuticals Inc
전화
781-419-1400
주소
730 THIRD AVENUE, NEW YORK, MA
Compare SNDX vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
19.99 | 1.76B | 217.42M | -243.25M | -278.35M | -2.7952 |
VRTX
Vertex Pharmaceuticals Inc
|
554.27 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
834.80 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,020.38 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
156.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.84 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-16 | 재개 | H.C. Wainwright | Buy |
| 2025-09-10 | 재개 | Stifel | Buy |
| 2025-09-04 | 재개 | Guggenheim | Buy |
| 2025-08-05 | 재확인 | BTIG Research | Buy |
| 2025-07-10 | 개시 | Goldman | Buy |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-06-28 | 개시 | Jefferies | Buy |
| 2024-01-31 | 다운그레이드 | Scotiabank | Sector Outperform → Sector Perform |
| 2023-12-22 | 개시 | Mizuho | Buy |
| 2023-10-25 | 개시 | BofA Securities | Buy |
| 2023-10-11 | 개시 | Goldman | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Outperform |
| 2023-07-11 | 개시 | Guggenheim | Buy |
| 2023-04-17 | 재개 | BTIG Research | Buy |
| 2023-01-31 | 개시 | Stifel | Buy |
| 2023-01-03 | 개시 | JP Morgan | Overweight |
| 2022-07-28 | 재개 | B. Riley Securities | Buy |
| 2022-04-11 | 개시 | H.C. Wainwright | Buy |
| 2022-02-15 | 개시 | Goldman | Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-05-25 | 개시 | Citigroup | Buy |
| 2021-02-18 | 개시 | B. Riley Securities | Buy |
| 2020-12-03 | 개시 | Stifel | Buy |
| 2020-05-22 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-05-22 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-05-18 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-05-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-13 | 재확인 | H.C. Wainwright | Buy |
| 2019-03-08 | 재확인 | H.C. Wainwright | Buy |
| 2019-01-04 | 개시 | Robert W. Baird | Outperform |
| 2018-01-05 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-03-16 | 개시 | FBR & Co. | Outperform |
| 2017-03-02 | 개시 | Instinet | Buy |
| 2016-10-07 | 개시 | Guggenheim | Buy |
| 2016-03-28 | 개시 | Citigroup | Buy |
| 2016-03-28 | 개시 | JMP Securities | Mkt Outperform |
| 2016-03-28 | 개시 | Morgan Stanley | Overweight |
모두보기
Syndax Pharmaceuticals Inc 주식(SNDX)의 최신 뉴스
SNDX Maintained by UBS -- Price Target Lowered to $33 - GuruFocus
UBS lowers Syndax Pharmaceuticals price target on revenue outlook By Investing.com - Investing.com Canada
Syndax (SNDX) Q2 2026 Earnings Call Transcript - AOL.com
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates - Eastern Progress
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Wall Street Analysts Think Syndax (SNDX) Could Surge 70.38%: Read This Before Placing a Bet - Eastern Progress
Syndax (SNDX) Quarterly Results: Profit Per Share Falls Below Its Benchmark in the Reported Period; Trading Move - vinanet.vn
Exploring 3 High Growth Tech Stocks In The US Market - Sahm
Syndax Pharmaceuticals (SNDX) Edges Up 0.46% to $19.85 as Range-Bound Trading PersistsHigh Low Breadth - vinanet.vn
GSA Capital Partners LLP Purchases New Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Stifel Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $40 - Moomoo
SNDX Stock Price, Quote & Chart - ChartMill
The Technical Signals Behind (SNDX) That Institutions Follow - Stock Traders Daily
Syndax (SNDX) Sales Nearly Doubled, So Why Did The Stock Fall? - Yahoo Finance
SNDX Maintained by JP Morgan -- Price Target Lowered to $40.00 - GuruFocus
Syndax Pharmaceuticals (NASDAQ:SNDX) Given New $40.00 Price Target at JPMorgan Chase & Co. - MarketBeat
J.P. Morgan Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Cuts Target Price to $40 - Moomoo
Syndax Pharmaceuticals (SNDX) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
Hennion & Walsh Asset Management Inc. Increases Stock Holdings in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Bank of America Corp DE Decreases Position in Syndax Pharmaceuticals, Inc. $SNDX - marketbeat.com
Net margin % of Syndax Pharmaceuticals Inc – HAM:1T3 - TradingView
Long term debt to total assets ratio of Syndax Pharmaceuticals Inc – HAM:1T3 - TradingView
Total common shares outstanding of Syndax Pharmaceuticals Inc – HAM:1T3 - TradingView
Price to sales forward of Syndax Pharmaceuticals Inc – HAM:1T3 - TradingView
State Street Corporation (SNDX) discloses 5.66M-share, 6.4% holding in Syndax - Stock Titan
How Surging Revuforj and Niktimvo Sales and Narrowing Losses Could Shape Syndax Pharmaceuticals (SNDX) Investors - Yahoo Finance
Syndax Pharmaceuticals Inc (1T3) Q3 2024 Earnings ReportResults, Call & Slides - tipranks.com
Earnings Update: Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Just Reported And Analysts Are Trimming Their Forecasts - simplywall.st
HC Wainwright Brokers Decrease Earnings Estimates for SNDX - MarketBeat
Syndax Pharmaceuticals Inc (1T3) Q1 2024 Earnings ReportResults, Call & Slides - tipranks.com
Surging Revenue And Narrower Losses Might Change The Case For Investing In Syndax Pharmaceuticals (SNDX) - webull.com
What is HC Wainwright's Estimate for SNDX FY2029 Earnings? - MarketBeat
BofA Securities Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Cuts Target Price to $26 - Moomoo
A Quick Look at Today's Ratings for Syndax Pharmaceuticals(SNDX.US), With a Forecast Between $26 to $57 - Moomoo
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Five New Syndax Employees Receive Stock Options With 4-Year Vesting - Stock Titan
Syndax Pharmaceuticals, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:SNDX) 2026-08-05 - Seeking Alpha
Syndax Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $38.27, Implies 101% Upside - TradingView
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap Down on Disappointing Earnings - MarketBeat
SNDX Maintains Rating by HC Wainwright & Co. -- Price Target Low - GuruFocus
HC Wainwright Has Lowered Expectations for Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price - marketbeat.com
Sei Investments Co. Grows Stake in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals Inc (SNDX) (Q2 2026) Earnings Call Highli - GuruFocus
SNDX Q2 2026 Sales Surge Highlights Growth Potential Despite Val - GuruFocus
Syndax Pharmaceuticals Inc (SNDX) (Q2 2026) Earnings Call Highlights: Revenue Surges 92% as ... - Yahoo! Finance Canada
SNDX SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Syndax Pharmaceuticals Q2 Earnings Call Highlights - marketbeat.com
Syndax Pharmaceuticals (SNDX) Q2 Revenue Miss Highlights Valuati - GuruFocus
Is Syndax Pharmaceuticals Inc (SNDX) Facing Value Challenges Aft - GuruFocus
SNDX: Q2 revenue surged 92% year-over-year, driven by strong Revuforj and Niktimvo growth - TradingView
Syndax Pharmaceuticals (NASDAQ:SNDX) Releases Quarterly Earnings Results - MarketBeat
Syndax Pharmaceuticals Inc (SNDX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.98%
자본화:
|
볼륨(24시간):